Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sunshine Guojian Pharmaceutical (Shanghai) Co's interest expense for the
three
months ended in Mar. 2026 was ¥ -39 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-50 Mil.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-39 Mil. Its
Operating Income
for the
three
months ended in Mar. 2026 was ¥191 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2026 was ¥0 Mil.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd has no debt.
Sunshine Guojian Pharmaceutical (Shanghai) Co Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Interest Expense Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Sunshine Guojian Pharmaceutical (Shanghai) Co Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Interest Expense of ¥-50 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Interest Expense too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Interest Expense is ¥-50 Mil. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Interest Expense compare to VRTX and REGN?
Sunshine Guojian Pharmaceutical (Shanghai) Co's Interest Expense of ¥-50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Interest Expense is ¥-50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥67.43, compared to a current price of ¥42.70 — trading 36.7% below its estimated fair value. The current Interest Expense is ¥-50 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Interest Expense is ¥-50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥42.70 is trading 36.7% below its estimated GF Value™ of ¥67.43.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.
Key valuation signals for SHSE:688336:
Interest Expense: ¥-50 Mil
GF Value™: ¥67.43 vs. price of ¥42.70 (36.7% below fair value)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
81GF Score
Get the complete analysis for SHSE:688336
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
